3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Classical hematology
1
CNS
1
Breast
1
Conditions
Brain Neoplasms
593
Glioblastoma
573
Glioma
298
Central Nervous System Neoplasms
208
Gliosarcoma
177
Neuroblastoma
175
Astrocytoma
174
Oligodendroglioma
112
Carcinoma, Non-Small-Cell Lung
92
Medulloblastoma
80
Breast Neoplasms
74
Ependymoma
61
Sarcoma
60
Meningioma
60
Neoplasm Metastasis
57
Recurrence
56
Melanoma
56
Neoplasms
51
Lung Neoplasms
48
Neurofibromatosis 1
43
Meningeal Carcinomatosis
40
Osteosarcoma
39
Pheochromocytoma
38
Rhabdomyosarcoma
37
Wilms Tumor
36
Paraganglioma
35
Lymphoma, Non-Hodgkin
32
Neuroectodermal Tumors, Primitive, Peripheral
29
Lymphoma
27
Sarcoma, Ewing
26
Interventions
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Second Primary
×
CNS
×
Clear all
NCT00638963
2017-06-14
STOP
Merck Sharp & Dohme LLC
Phase 2
Terminated
6 enrolled
9 charts